This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (571) Pharmacology and Pharmaceutics (66) Neurology and Neurosciences (185)

Published on in Vol 10, No 10 (2021): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/24969, first published .
Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)

Authors of this article:

Vicki E Maltby1, 2, 3 Author Orcid Image ;   Rodney A Lea2, 3, 4 Author Orcid Image ;   Mastura Monif5, 6, 7 Author Orcid Image ;   Marzena J Fabis-Pedrini8 Author Orcid Image ;   Katherine Buzzard5, 7 Author Orcid Image ;   Tomas Kalincik7, 9 Author Orcid Image ;   Allan G Kermode8, 10 Author Orcid Image ;   Bruce Taylor11 Author Orcid Image ;   Suzanne Hodgkinson12, 13, 14 Author Orcid Image ;   Pamela McCombe15 Author Orcid Image ;   Helmut Butzkueven6, 9 Author Orcid Image ;   Michael Barnett16, 17 Author Orcid Image ;   Jeannette Lechner-Scott1, 2, 3 Author Orcid Image
Article Authors Cited by (5) Tweetations (2) Metrics

Journals

  1. Seiberl M, Feige J, Hilpold P, Hitzl W, Machegger L, Buchmann A, Khalil M, Trinka E, Harrer A, Wipfler P, Moser T. Serum Neurofilament Light Chain as Biomarker for Cladribine-Treated Multiple Sclerosis Patients in a Real-World Setting. International Journal of Molecular Sciences 2023;24(4):4067 View
  2. Giovannoni G, Mathews J. Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review. Neurology and Therapy 2022;11(2):571 View
  3. Centonze D, Amato M, Brescia Morra V, Cocco E, De Stefano N, Gasperini C, Gallo P, Pozzilli C, Trojano M, Filippi M. Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4. Therapeutic Advances in Neurological Disorders 2023;16 View
  4. Aran K, Gupta G, Singh S. Cryptotanshinone ameliorates cladribine-induced cognitive impairment in rats. Asian Pacific Journal of Tropical Biomedicine 2023;13(7):296 View
  5. Arun T, Shehu A, Pye E, Smith L, Meehan M. Treatment continuation with cladribine at 5 years after initiation in people with multiple sclerosis: A case series and literature review. Multiple Sclerosis and Related Disorders 2024;90:105837 View